The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Abstract
BACKGROUND: Preclinical studies in animal models have demonstrated tumor regression following intratumoral administration of an adenovirus vector containing wild-type p53 complementary DNA (Ad-p53). Therefore, in a phase I clinical trial, we administered Ad-p53 to 28 patients with non-small-cell lung cancer (NSCLC) whose cancers had progressed on conventional treatments. METHODS: Patients received up to six, monthly intratumoral injections of Ad-p53 by use of computed tomography-guided percutaneous fine-needle injection (23 patients) or bronchoscopy (five patients). The doses ranged from 10(6) plaque-forming units (PFU) to 10(11) PFU. RESULTS: Polymerase chain reaction (PCR) analysis showed the presence of adenovirus vector DNA in 18 (86%) of 21 patients with evaluable posttreatment biopsy specimens; vector-specific p53 messenger RNA was detected by means of reverse transcription-PCR analysis in 12 (46%) of 26 patients. Apoptosis (programmed cell death) was demonstrated by increased terminal deoxynucleotide transferase-mediated biotin uridine triphosphate nick-end labeling (TUNEL) staining in posttreatment biopsy specimens from 11 patients. Vector-related toxicity was minimal (National Cancer Institute's Common Toxicity Criteria: grade 3 = one patient; grade 4 = no patients) in 84 courses of treatment, despite repeated injections (up to six) in 23 patients. Therapeutic activity in 25 evaluable patients included partial responses in two patients (8%) and disease stabilization (range, 2-14 months) in 16 patients (64%); the remaining seven patients (28%) exhibited disease progression. CONCLUSIONS: Repeated intratumoral injections of Ad-p53 appear to be well tolerated, result in transgene expression of wild-type p53, and seem to mediate antitumor activity in a subset of patients with advanced NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,003
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer.
Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., et al. (1996) · Nature Medicine · doi:10.1038/nm0996-985 · Cited by 703
Self-citationDai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., & Verma, I. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1401 · Cited by 591
P53, cell cycle control and apoptosis: Implications for cancer
Kastan, M. B., Canman, C. E., & Leonard, C. J. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690207 · Cited by 482
Bursch, W., Paffe, S., Putz, B., Barthel, G., & Schulte-Hermann, R. (1990) · Carcinogenesis · doi:10.1093/carcin/11.5.847 · Cited by 444
Clayman, G. L., el-Naggar, A. K., Lippman, S. M., Henderson, Y. C., Frederick, M., Merritt, J. A., Zumstein, L. A., Timmons, T. M., Liu, T. J., Ginsberg, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2221 · Cited by 371
Self-citation
Cited by
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
Hoffman, P. C., Mauer, A. M., & Vokes, E. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)82038-3 · Cited by 605
The molecular biology of cancer
Bertram, J. S. (2000) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(00)00007-8 · Cited by 585
The inhibitors of apoptosis (IAPs) as cancer targets
Hunter, A. M., LaCasse, E. C., & Korneluk, R. G. (2007) · Apoptosis · doi:10.1007/s10495-007-0087-3 · Cited by 565
Metadata
- Authors
- Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., Hong, W. K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., Mack, M., Merritt, J. A., Nguyen, D. M., Nesbitt, J. C., Perez-Soler, R., Pisters, K. M. W., Putnam, J. B., Richli, W. R., Savin, M., Schrump, D. S., Shin, D. M., Shulkin, A., Walsh, G. L., Wait, J., Weill, D., & Waugh, M. K. A.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-05-05
- Volume
- 91
- Issue
- 9
- Pages
- 763-771
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2021875656
- Cited by
- 496
- References
- 25
- FWCI
- 35.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1093/jnci/91.9.763
- The paper
- Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., Hong, W. K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., Mack, M., Merritt, J. A., Nguyen, D. M., Nesbitt, J. C., . . . Waugh, M. K. A. (1999). Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/91.9.763
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.